Three Seasons Wealth LLC Grows Position in Medpace Holdings, Inc. $MEDP

Three Seasons Wealth LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 322.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,657 shares of the company’s stock after buying an additional 1,265 shares during the quarter. Three Seasons Wealth LLC’s holdings in Medpace were worth $931,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its holdings in Medpace by 74.2% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,183 shares of the company’s stock valued at $664,000 after purchasing an additional 504 shares during the last quarter. Archford Capital Strategies LLC purchased a new position in shares of Medpace in the 4th quarter valued at about $949,000. Allspring Global Investments Holdings LLC increased its stake in shares of Medpace by 164.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock valued at $2,086,000 after purchasing an additional 2,274 shares in the last quarter. Brookstone Capital Management acquired a new position in Medpace in the 4th quarter worth about $216,000. Finally, Polianta Ltd purchased a new position in Medpace during the fourth quarter worth approximately $1,572,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent analyst reports. Barclays upgraded Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 target price on the stock in a research report on Friday, March 6th. Leerink Partners lowered their target price on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target on the stock in a research report on Tuesday, February 10th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Finally, Truist Financial decreased their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $486.67.

Medpace Price Performance

MEDP stock opened at $480.19 on Wednesday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The business’s 50-day moving average is $488.61 and its two-hundred day moving average is $537.50. The firm has a market capitalization of $13.63 billion, a P/E ratio of 31.38, a P/E/G ratio of 2.21 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm’s revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insiders Place Their Bets

In related news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.30% of the stock is currently owned by insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.